• 1
    Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families.The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678701.
  • 2
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers.Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 26571.
  • 3
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers.Breast Cancer Linkage Consortium. Lancet 1994; 343: 6925.
  • 4
    Struewing JP, Tarone RE, Brody LC, Li FP, Boice JDJr. BRCA1 mutations in young women with breast cancer. Lancet 1996; 347: 1493.
  • 5
    Struewing JP, Hartge P, Wacholdes S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 14018.
  • 6
    Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 1997; 60: 48695.
  • 7
    Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63: 4551.
  • 8
    Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 67689.
  • 9
    Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE. Population based study of risk of breast cancer in carriers of BRCA2 mutations. Lancet 1998; 352: 13379.
  • 10
    Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000; 83: 13018.
  • 11
    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 111730. Erratum in: Am J Hum Genet 2003;73:709.
  • 12
    King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 6436.
  • 13
    Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, Lenoir G, Lynch H. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64: 3948.
  • 14
    Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Oral contraceptives and the risk of hereditary ovarian cancer.Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 4248.
  • 15
    Jernström H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354: 184650.
  • 16
    Nathanson KN, Weber BL. ‘Other’ breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 2001; 10: 71520.
  • 17
    Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002; 2: 11323.
  • 18
    Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64: 13717.
  • 19
    Chen JD, Li H. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Crit Rev Eukaryot Gene Expr 1998; 8: 16990.
  • 20
    Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001; 61: 9037.
  • 21
    Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor co-activator amplified in breast and ovarian cancer. Science 1997; 277: 9658.
  • 22
    Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Melzer P, Theiller C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998; 4: 29259.
  • 23
    Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004; 24: 515771.
  • 24
    Reiter R, Oh AS, Wellstein A, Riegel AT. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 2004; 23: 4039.
  • 25
    Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999; 154: 52536.
  • 26
    Sakakura C, Hagiwara A, Yasuka R, Fujita Y, Nakanishi M, Masuda K, Kimura A, Nakamura Y, Inazawa J, Abe T, Yamagishi H. Amplification and over-statement of the AIB1 nuclear receptor co-activator gene in primary gastric cancer. Int J Cancer 2000; 89: 21723.
  • 27
    Shirazi SK, Bober MA, Coetzee GA. Polymorphic exonic CAG microsatellites in the gene amplified in breast cancer (AIB1 gene). Clin Genet 1998; 54: 1023.
  • 28
    Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999; 19: 838392.
  • 29
    Chamberline N, Driver E, Miesfeld R. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acid Res 1994; 22: 31816.
  • 30
    Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, et al. Modification of BRCA1 and BRCA2 associated breast cancer risk by the AIB1 genotype and reproductive history. Cancer Res 2001; 61: 54204.
  • 31
    Kadouri L, Kote-Jarai Z, Easton DF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 2004; 108: 399403.
  • 32
    Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willet WC, Speizer FE, Brown M, Hunter DJ. Polymorphic repeat in AIB1 does not alter breast cancer risk. Breast Cancer Res 2000; 2: 37885.
  • 33
    Wilkening S, Burwinkel B, Grzybowska E, Klaes R, Pamula J, Pekala W, Zientek H, Hemminki K, Forsti A. Polyglutamine repeat length in the NCOA3 does not affect risk in familial breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2912.
  • 34
    Lin DY, Wei LJ. Robust inference for the Cox proportional hazards model. J Am Stat Assn 1989; 84: 10748.
  • 35
    Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer (Phila) 1997; 80: 43541.
  • 36
    Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11: 33741.